This article is more than 5 years old. Information may no longer be current.
Dana-Farber Cancer Institute professor to join Eli Lilly as senior VP for oncology
Levi Garraway, MD, PhD, has been appointed senior vice president of global development and medical affairs for oncology.
Garraway, recognized for his expertise in the analysis of cancer genomics and resistance to targeted therapies, will succeed Richard Gaynor, MD, who is retiring.
Garraway —who serves as associate professor of medicine in the department of medical oncology at Dana-Farber Cancer Institute and Harvard Medical School, as well as associate physician at Brigham and Women’s Hospital — will join Lilly on Jan. 1.
Garraway is director of the Joint Center for Cancer Precision Medicine, a collaboration between Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital and Broad Institute. He also is co-leader of the cancer genetics program at Dana-Farber/Harvard Cancer Center, as well as a founder of Foundation Medicine, a cancer genomics diagnostic company.
“We are pleased and honored to have Dr. Garraway join us at Lilly,” Sue Mahony, PhD, Lilly senior vice president and president of Lilly Oncology, said in a press release. “He has made a tremendous impact in his career and is recognized around the world as a leader in oncology. We know he will provide keen insight and expertise — and will continue to advance Lilly's work in developing innovative new medicines to truly make life better for people with cancer around the world.”
Mahony also praised Gaynor for his contributions to the development and discovery of cancer medicines.
“Richard is known for scientific rigor and deep expertise in drug development, coupled with a personal warmth and care for patients that is truly inspiring,” she said. “He is leaving a remarkable legacy at Lilly through his impact on the pipeline, people and patients.”